Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.

被引：6
|
作者：
Antonarakis, Emmanuel S.
Goh, Jeffrey C.
Gross-Goupil, Marine
Vaishampayan, Ulka N.
Piulats, Josep M.
De Wit, Ronald
Alanko, Tuomo
Fukasawa, Satoshi
Tabata, Kenichi
Feyerabend, Susan
Berger, Raanan
Wu, Haiyan
Kim, Jeri
Poehlein, Christian Heinrich
De Bono, Johann S.
机构：
[1] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Royal Brisbane & Womens Hosp, Herston, Qld, Australia
[3] Univ Hosp Bordeaux, Bordeaux, France
[4] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[5] Hosp Duran & Reynals, Inst Catalan Oncol, Barcelona, Spain
[6] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[7] Docrates Canc Ctr, Helsinki, Finland
[8] Chiba Canc Ctr, Chiba, Japan
[9] Kitasato Univ, Sch Med, Sagamihara, Kanagawa, Japan
[10] Chaim Sheba Med Ctr, Tel Hashomer, Israel
[11] MSD China, Beijing, Peoples R China
[12] Merck & Co Inc, Kenilworth, NJ USA
[13] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.216
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
216
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.
    Petrylak, Daniel P.
    Ratta, Raffaele
    Matsubara, Nobuaki
    Korbenfeld, Ernesto Pablo
    Gafanov, Rustem
    Mourey, Loic
    Todenhofer, Tilman
    Gurney, Howard
    Kramer, Gero
    Bergman, Andre M.
    Zalewski, Pawel
    De Santis, Maria
    Armstrong, Andrew J.
    Gerritsen, Winald R.
    Pachynski, Russell Kent
    Byun, Seok-Soo
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian Heinrich
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [32] KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update
    Omlin, A. G.
    Graff, J. N.
    Hoimes, C. J.
    Tagawa, S. T.
    Hwang, C.
    Kilari, D.
    Ten Tije, A. J.
    McDermott, R.
    Vaishampayan, U. N.
    Elliott, T.
    Gerritsen, W. R.
    Wu, H.
    Kim, J.
    Schloss, C.
    de Bono, J. S.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S514 - S515
  • [33] Response to cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) poorly responding to docetaxel
    Angelergues, A.
    Bellmunt, J.
    Efstathiou, E.
    Gonzalez, I.
    Gyftaki, R.
    Delanoy, N.
    Ozguroglu, M.
    Flechon, A.
    Guillot, A.
    Le Moulec, S.
    Castellano, D.
    Esteban, E.
    Munarriz, J.
    Campos Balea, B.
    Ardavanis, A.
    Stefanou, D.
    Oudard, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S488 - S488
  • [34] Docetaxel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC): an Observational Study in a Single Institution
    Schallier, D.
    Decoster, L.
    Braeckman, J.
    Fontaine, C.
    Degreve, J.
    ANTICANCER RESEARCH, 2012, 32 (02) : 633 - 641
  • [35] Biomarker Analysis of Men With Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer Treated With Pembrolizumab
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 15 - 16
  • [36] PHASE 3 TRIAL OF PEMBROLIZUMAB AND ENZALUTAMIDE VERSUS ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) (KEYNOTE-641)
    Graff, Julie Nicole
    Burgents, Joseph
    Liang, Li Wen
    Stenzl, Arnulf
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A210 - A210
  • [37] Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Schnadig, Ian D.
    Bhor, Menaka
    Vogelzang, Nicholas J.
    Hennessy, Daniel
    Nicacio, Leonardo V.
    Berry, William R.
    Hutson, Thomas E.
    Fleming, Mark T.
    Cowey, C. Lance
    Saravanan, Shanmugapriya
    Dhanda, Rahul
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [38] Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
    Baciarello, Giulia
    Sternberg, Cora N.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 106 : 14 - 24
  • [39] BURDEN OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN TURKEY
    Erdal, E.
    Malhan, S.
    Oksuz, E.
    Benekli, M.
    Cag, C.
    Dane, F.
    Kabasakal, L.
    Kucuk, O.
    Sozen, T. S.
    Sar, C.
    Kahveci, B.
    VALUE IN HEALTH, 2016, 19 (07) : A725 - A726
  • [40] Testosterone levels in metastatic castration-resistant prostate cancer (mCRPC).
    von Klot, Christoph A. J.
    Boeker, Alena
    Herrmann, Thomas R. W.
    Kramer, Mario W.
    Kuczyk, Markus A.
    Merseburger, Axel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
12345